Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRILAFON vs LEVOPROME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.
Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.
Schizophrenia,Schizoaffective disorder,Severe nausea and vomiting (in adults),Bipolar disorder (off-label)
Psychotic disorders,Schizophrenia,Acute mania,Nausea and vomiting,Intractable hiccups
8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.
25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.
Terminal elimination half-life is approximately 10–20 hours (mean ~12 hours); supports twice-daily dosing.
Terminal elimination half-life is approximately 24 hours (range 12–36 hours). Accumulation occurs with repeated dosing, requiring dose adjustment in hepatic impairment.
Extensively metabolized in the liver via glucuronidation, sulfoxidation, side-chain oxidation, and N-dealkylation. CYP2D6 is a major enzyme involved in metabolism; polymorphisms can lead to poor metabolizer status.
Hepatic via CYP2D6, CYP3A4; active metabolites include methotrimeprazine sulfoxide, N-desmethylmethotrimeprazine.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for the majority of elimination.
Primarily renal (approx. 70% as conjugated metabolites, <1% unchanged), with biliary/fecal excretion (approx. 20%).
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
>99% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 10–15 L/kg; large Vd indicates extensive tissue distribution.
Approximately 7 L/kg (range 5–10 L/kg), indicating extensive tissue distribution.
Oral: 40–50% (due to first-pass metabolism); IM: 100% (assumed complete absorption).
Oral: 40–50% (first-pass effect); Intramuscular: 70–80%.
No dosage adjustment required for GFR 10-50 m L/min; use 50% of normal dose if GFR <10 m L/min.
Cr Cl 10-50 m L/min: Administer 75% of usual dose; Cr Cl <10 m L/min: Administer 50% of usual dose.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 25-50%; Child-Pugh Class C: Avoid use.
Not recommended for children under 12 years; for ages 12 and older, 6-12 mg orally 2-3 times daily; maximum 24 mg/day.
Children >12 years: 0.5-1 mg/kg intramuscularly every 6-8 hours; maximum 2 mg/kg/day. Not recommended for children under 12 years.
Initiate at 4-8 mg orally daily; increase slowly; monitor for QT prolongation, hypotension, and tardive dyskinesia.
Initial dose: 12.5 to 25 mg intramuscularly; titrate cautiously due to increased sensitivity and risk of orthostatic hypotension.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Perphenazine is not approved for the treatment of dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis; risk of tardive dyskinesia; neuroleptic malignant syndrome (NMS).
Extrapyramidal symptoms (including tardive dyskinesia) may occur,Neuroleptic malignant syndrome (NMS) - potentially fatal,QT prolongation and risk of arrhythmias,Orthostatic hypotension,Seizures (lower seizure threshold),Leukopenia, neutropenia, and agranulocytosis,Hematologic toxicity,Hyperprolactinemia,Cognitive and motor impairment,Antiemetic effect may mask signs of toxicity or overdose,Use in elderly with dementia not approved
Neuroleptic malignant syndrome, tardive dyskinesia, hypotension, seizures, anticholinergic effects, QT prolongation, agranulocytosis, photosensitivity, elevation of prolactin levels.
Hypersensitivity to perphenazine or any component of the formulation,Comatose states,CNS depression due to alcohol, barbiturates, or other drugs,Subcortical brain damage,Blood dyscrasias,Bone marrow suppression,Severe hypotension,Known QT prolongation or concurrent use with QT-prolonging drugs
Comatose states, CNS depression, bone marrow suppression, pheochromocytoma, hypersensitivity to phenothiazines, concurrent use with high-dose CNS depressants.
Avoid grapefruit and grapefruit juice as they may increase perphenazine levels. Limit caffeine intake as it may worsen side effects like restlessness. Taking with food may reduce GI upset but avoid high-fat meals which can affect absorption.
Avoid grapefruit and grapefruit juice as they may increase serum levels of methotrimeprazine. Limit caffeine intake as it may exacerbate side effects like restlessness. No specific food restrictions otherwise.
First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal in neonates after late third trimester exposure. Overall, use only if benefit outweighs risk; avoid during organogenesis.
First trimester: Limited data; animal studies show increased fetal resorption and skeletal anomalies at high doses. Second and third trimesters: No evidence of major malformations; risk of neonatal extrapyramidal symptoms and jaundice with third-trimester use.
Trilafon (perphenazine) is excreted into human milk in small amounts; M/P ratio unknown. Monitor infant for drowsiness, irritability, or movement disorders. Use with caution during breastfeeding.
Levofloxacin (levoprome) is excreted in human milk; M/P ratio approximately 0.8. Avoid breastfeeding during therapy due to potential adverse effects on infant cartilage development.
No established dose adjustment per se; start at lowest effective dose. Increased plasma volume and metabolism during pregnancy may require dose increases to maintain efficacy; individualize based on response and tolerability.
No dosage adjustment required based on pregnancy-related pharmacokinetic changes; however, use only if clearly needed due to theoretical risks to fetus.
TRILAFON (perphenazine) is a typical antipsychotic with potent antiemetic properties. Monitor for extrapyramidal symptoms (EPS), especially akathisia and dystonia. Avoid use in patients with CNS depression or bone marrow suppression. May lower seizure threshold; use cautiously in epilepsy. QT prolongation risk requires ECG monitoring. Taper dose when discontinuing to avoid withdrawal dyskinesias.
Levoprome (methotrimeprazine) is a phenothiazine neuroleptic with potent analgesic properties. It may cause significant hypotension, especially in elderly or hypovolemic patients; use with caution and monitor blood pressure. Extrapyramidal symptoms are less common than with typical antipsychotics but may occur. Avoid subcutaneous extravasation due to tissue irritation.
Avoid alcohol and other CNS depressants.,Report any involuntary muscle movements, stiffness, or restlessness immediately.,May cause drowsiness; avoid driving until you know how the medication affects you.,Rise slowly from sitting or lying to prevent dizziness.,Use sun protection as this drug may increase sensitivity to sunlight.,Do not stop taking abruptly without consulting your doctor.,Inform all healthcare providers that you are taking this medication.
This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Avoid alcohol and other central nervous system depressants.,Rise slowly from sitting or lying positions to prevent fainting.,Report any unusual muscle movements or stiffness to your healthcare provider.,Use sunscreen and protective clothing as this drug may increase sensitivity to sunlight.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRILAFON vs LEVOPROME, answered by our medical review team.
TRILAFON is a Phenothiazine Antipsychotic that works by Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.. LEVOPROME is a Phenothiazine Antipsychotic that works by Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRILAFON and LEVOPROME depend on the specific clinical indication. These are both Phenothiazine Antipsychotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRILAFON is: 8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.. The standard adult dose of LEVOPROME is: 25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRILAFON and LEVOPROME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRILAFON is classified as Category C. First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or with. LEVOPROME is classified as Category C. First trimester: Limited data; animal studies show increased fetal resorption and skeletal anomalies at high doses. Second and third trimesters: No evidence of major malformations;. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.